Does SATRALIZUMAB Cause Hepatic function abnormal? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Hepatic function abnormal have been filed in association with SATRALIZUMAB (Enspryng). This represents 2.7% of all adverse event reports for SATRALIZUMAB.
6
Reports of Hepatic function abnormal with SATRALIZUMAB
2.7%
of all SATRALIZUMAB reports
1
Deaths
4
Hospitalizations
How Dangerous Is Hepatic function abnormal From SATRALIZUMAB?
Of the 6 reports, 1 (16.7%) resulted in death, 4 (66.7%) required hospitalization.
Is Hepatic function abnormal Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SATRALIZUMAB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does SATRALIZUMAB Cause?
Neuromyelitis optica spectrum disorder (46)
Off label use (26)
Urinary tract infection (21)
Muscular weakness (19)
Optic neuritis (15)
Hypoaesthesia (14)
Infection (14)
Pneumonia (13)
Covid-19 (11)
Fatigue (11)
What Other Drugs Cause Hepatic function abnormal?
NIVOLUMAB (1,131)
PEMBROLIZUMAB (1,079)
METHOTREXATE (1,054)
CABOZANTINIB S-MALATE (912)
CYCLOPHOSPHAMIDE (824)
BEVACIZUMAB (769)
PACLITAXEL (603)
LENVATINIB (528)
ATORVASTATIN (520)
CYCLOSPORINE (508)
Which SATRALIZUMAB Alternatives Have Lower Hepatic function abnormal Risk?
SATRALIZUMAB vs SATRALIZUMAB-MWGE
SATRALIZUMAB vs SAXAGLIPTIN
SATRALIZUMAB vs SCHOLL'S INGROWN TOENAIL PAIN RELIEVER
SATRALIZUMAB vs SCOPOLAMINE
SATRALIZUMAB vs SCOPOLAMINE HYDROBROMIDE